ProShares Trust - ProShares UltraPro Dow30 3x Shares
UDOW
Get informed when a big investor buys or sells
+ FollowMarket Cap$25.8B
Close$
Share Statistics
| Market cap | $25.80 Billion |
|---|---|
| Enterprise Value | $25.62 Billion |
| Dividend Yield | $0.77 (1.14%) |
| Earnings per Share | $- |
| Beta | 2.6 |
| Outstanding Shares | - |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1962.05 |
| Enterprise Value to EBIT | -340.86 |
| Enterprise Value to Net Income | -364 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5623▲ 16.26% |
|---|---|
| Total Calls | 843,200▲ 0.84% |
| Total Puts | 474,100▲ 41.86% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.98%▼ 8.16% |
|---|---|
| Total Invested | $41.82M▼ 61.47% |
| Investors Holding | 63▼ 5.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...